The Impact of FDA’s New Ruling on Laboratory Billing

The FDA’s new ruling on LDTs is critical in regulating laboratory-developed diagnostic products. Understanding the implications of the ruling for medical billing practices is important. We can successfully navigate this evolving regulatory landscape by proactively adapting billing processes, prioritizing regulatory compliance, and advocating for patient-centric care. Here are some of the implications of the new […]